Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0JXYIZ
ADC Name
DS-9606a
Synonyms
DS 9606; DS-9606; DS9606; DS 9606a; DS9606a
   Click to Show/Hide
Organization
Daiichi Sankyo Co., Ltd.
Drug Status
Phase 1
Indication
In total 2 Indication(s)
Ovarian cancer
Phase 1
Clinical Trial
Solid tumor
Phase 1
Clinical Trial
Drug-to-Antibody Ratio
Undisclosed
Antibody Name
Undisclosed
Antigen Name
Claudin-6 (CLDN6)
  Antigen Info 
Payload Name
modified PBD
  Payload Info 
Therapeutic Target
Human Deoxyribonucleic acid (hDNA)
  Target Info 
Linker Name
Undisclosed
Conjugate Type
Undisclosed
Puchem SID
355210663
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type NCT Number Clinical Status Clinical Trial Description
Undisclosed  NCT05394675
Phase 1
A phase 1, first-in-human study of DS-9606a in patients with tumor types known to express claudin-6 (CLDN6).
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Related Clinical Trial
NCT Number NCT05394675  Clinical Status Phase 1
Clinical Description A phase 1, first-in-human study of DS-9606a in patients with tumor types known to express claudin-6 (CLDN6).
References
Ref 1 A Phase 1, First-in-Human Study of DS-9606a in Patients With Tumor Types Known to Express Claudin-6 (CLDN6), NCT05394675